You are here

Home » Content

Metabolik Sendrom ve Cinsiyet: Doku Doppler Çalışması

Metabolic syndrome and Gender Difference: Tissue Doppler Study

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2012
DOI: 
http://dx.doi.org/10.5505/abantmedj.2012.35744

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Background: Metabolic syndrome (MS) is a cluster of cardiovascular risk factors. Gender difference has different effects on cardiac functions in MS and this has been thought to be decisive in terms of interference. In this study, we aimed to investigate the effect gender differences MS patients with tissue Doppler echocardiography. Method: The study population consisted of 83 females and 87 males with the diagnosis of MS. All the study population underwent a detailed echocardiography with tissue Doppler parameters of systolic myocardial velocity (Sm), early diastolic velocity (Em) and late diastolic velocity (Am) were measured from septal, lateral, and right ventricular annulus. Myocardial performance index (MPI) was calculated by dividing the sum of isovolumetric relaxation and isovolumetric contractine times by ejection time. Results: While there were no significant differences in early and late diastolic velocities, septal, lateral Sm measurements and septal MPI were significantly higher in men than in women (p values: 0,007, 0,001 and 0,027 respectively). Right ventricle and lateral MPI were comparable between study groups. Besides septal and lateral ejection times were significantly higher in men when compared to women (p values: 0,016 and 0,012 respectively). Conclusion: Cardiac functions in patients with metabolic syndrome differ between the sexes. The different effect of MS on sexes is important in the development of patientoriented treatment strategies in terms of improving the treatment of coronary artery disease and risk factors.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Metabolik sendrom (MS) kardiyak fonksiyonlar üzerine zararlı etkileri olan risk faktörleri kümesidir. Cinsiyet farkının metabolik sendromun kardiyak fonksiyonlar üzerinde farklı etkileri olduğu ve daha fazla etkilenme açısından belirleyici olduğu düşünülmektedir. Biz bu çalışmamızda MS hastalarında cinsiyet farkının kardiyak fonksiyonlar üzerine olan etkisini doku Doppler tekniği kullanarak araştırmayı amaçladık. Yöntem: Çalışmaya MS tanısı konan 83 kadın ve 87 erkek hasta alınmıştır. Bu hastalara ayrıntılı transtorasik ekokardiyografi yapılarak doku Doppler parametreleri olan sistolik miyokardiyal hız (Sm), erken diyastolik hız (Em) ve geç diyastolik hız (Am), septal, lateral ve sağ ventrikül bölgelerinden ölçüldü. Miyokard performans indeksi (MPİ) isovolümetrik kontraksiyon ve relaksasyon zamanlarının toplamının aortik ejeksiyon zamanına oranı olarak hesaplandı. Bulgular: Erken ve geç diyastolik hızlarda fark saptanmazken septal, lateral Sm değerleri ve septal MPI erkeklerde kadınlara göre anlamlı şekilde yüksek saptandı (p değeri sırasıyla 0,007, 0,001 ve 0,027) Sağ ventrikül ve lateral MPI değerlerinde fark saptanmadı. Ayrıca septal ve lateral ejeksiyon zamanı değerleri erkeklerde anlamlı şekilde yüksek saptandı (p değeri sırasıyla 0,016 ve 0,012). Sonuç: Metabolik sendromlu hastalarda kardiyak fonksiyonlar cinsiyetler arasında farklılık göstermektedir. Metabolik sendromun farklı cinsiyetlerde etkisinin farklı olması, birey odaklı tedavi stratejileri geliştirmek açısından değerlendirildiğinde koroner arter hastalığı ve risk faktörlerinin tedavisinde farklı yaklaşımlar geliştirilmesinde önemlidir.
FULL TEXT (PDF): 
PDF icon arastirmax-metabolik-sendrom-cinsiyet-doku-doppler-calismasi.pdf
  • 2
39-44
  • Turkish

REFERENCES

References: 

1. Dursunoğlu D, Evrengül H, Tanriverdi H, Kuru O, Gür S,
Kaftan A, Kiliç M. Do female patients with metabolic
syndrome have masked left ventricular dysfunction?
Anadolu Kardiyol Derg, 2005; 5: p. 283-8.
2. Ford ES., WH. Giles, and WH. Dietz. Prevalence of the
metabolic syndrome among US adults: findings from the
third National Health and Nutrition Examination Survey.
JAMA, 2002. 287: p. 356-9.
3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo
E, Tuomilehto J, Salonen JT. The metabolic syndrome
and total and cardiovascular disease mortality in
middle-aged men. JAMA. 2002:4;288:2709-16.
4. Onat A, Ceyhan K, Başar O, Erer B, Toprak S, Sansoy V.
Metabolic syndrome: major impact on coronary risk in a
population with low cholesterol levels--a prospective
and cross-sectional evaluation. Atherosclerosis, 2002.
165: p. 285-92.
5. Ozsahin AK, Gokcel A, Sezgin N, Akbaba M, Guvener N,
Ozisik L, Karademir BM. Prevalence of the metabolic
syndrome in a Turkish adult population. Diabetes Nutr
Metab, 2004. 17: p. 230-4.
6. Reaven GM. Banting lecture 1988. Role of insulin resistance
in human disease. Diabetes, 1988. 37: p. 1595-
607.
7. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella
JN, Liu JE, Resnick HE, Lee ET, Best LG, de Simone G.
Comparison of cardiac structure and function in American
Indians with and without the metabolic syndrome
(the Strong Heart Study). Am J Cardiol, 2004. 93: p. 40-
4.
8. Murphy JG., MA. Lloyd, and Mayo Clinic. Mayo Clinic
cardiology: concise textbook. 3rd ed. 2007, Rochester,
MN: Mayo Clinic Scientific Press: Informa Healthcare
USA. XXIII, 1580 p.
9. Eric J. Topol, Robert M. Califf, Jeffrey Isner, Eric N. Prystowsky,
Judith Swain, James Thomas, Paul Thompson,
James B. Young. Textbook of cardiovascular medicine.
2nd ed. 2002, Philadelphia: Lippincott Williams & Wilkins.
XXI, 2210 p.
10. Knopp RH., X. Zhu, and B. Bonet. Effects of estrogens on
lipoprotein metabolism and cardiovascular disease in
women. Atherosclerosis, 1994. 110 Suppl: p. S83-91.
11. Knopp R, Poirier P. Exaggerated lipoprotein abnormalities
in diabetic women as compared with diabetic
men:possible significan ce fo atherosclerosis. cardiovascular health and disease
in women, 1993: p. 131-138
12. Hokanson JE. and MA. Austin. Plasma triglyceride level
is a risk factor for cardiovascular disease independent of
high-density lipoprotein cholesterol level: a metaanalysis
of population-based prospective studies. J Cardiovasc
Risk, 1996. 3: p. 213-9.
13. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli
WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler
HA. High-density lipoprotein cholesterol and cardiovascular
disease. Four prospective American studies. Circulation,
1989. 79: p. 8-15.
14. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F,
Siepi D, Vaudo G, Mannarino E.
15. Different impact of the metabolic syndrome on left
ventricular structure and function in hypertensive men
and women. Hypertension, 2006. 47: p. 881-6.
16. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern
MP. San Antonio Heart Study., National Cholesterol
Education Program versus World Health Organization
metabolic syndrome in relation to all-cause and cardiovascular
mortality in the San Antonio Heart Study. Circulation,
2004. 110: p. 1251-7.
17. Turhan H, Yasar AS, Yagmur J, Kurtoglu E, Yetkin E. The
impact of metabolic syndrome on left ventricular function:
evaluated by using the index of myocardial performance.
Int J Cardiol, 2009. 132: p. 382-6.
18. Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) final report. Circulation,
2002. 106: p. 3143-421.
19. Griffin Brian P; Topol Eric J. Manual of cardiovascular
medicine. 3rd ed. 2009, Philadelphia: Wolters
Kluwer/Lippincott Williams & Wilkins. xvii, 1015 p.
20. Chinali M, de Simone G, Roman MJ, Best LG, Lee ET,
Russell M, Howard BV, Devereux RB. Cardiac markers of
preclinical disease in adolescents with the metabolic
syndrome. JACC. 2008; 52:932-8
21. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F,
Siepi D, Vaudo G, Mannarino E. Different impact of the
metabolic syndrome on left ventricular structure and
function in hypertention men and women. Hypertension.
2006;47:881-886.

Thank you for copying data from http://www.arastirmax.com